Chicago Equity Partners LLC Acquires 1,483 Shares of ANI Pharmaceuticals Inc (ANIP)
Chicago Equity Partners LLC grew its holdings in ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 3.9% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 39,558 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,483 shares during the quarter. Chicago Equity Partners LLC’s holdings in ANI Pharmaceuticals were worth $2,237,000 as of its most recent SEC filing.
Several other institutional investors have also made changes to their positions in ANIP. Piedmont Investment Advisors LLC bought a new stake in shares of ANI Pharmaceuticals in the second quarter valued at about $140,000. Truvestments Capital LLC bought a new stake in shares of ANI Pharmaceuticals in the third quarter valued at about $152,000. Crossmark Global Holdings Inc. bought a new stake in shares of ANI Pharmaceuticals in the second quarter valued at about $235,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp bought a new stake in shares of ANI Pharmaceuticals in the second quarter valued at about $267,000. Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of ANI Pharmaceuticals in the second quarter valued at about $272,000. 61.10% of the stock is owned by institutional investors.
ANIP opened at $52.66 on Friday. ANI Pharmaceuticals Inc has a twelve month low of $48.40 and a twelve month high of $74.70. The company has a debt-to-equity ratio of 1.04, a current ratio of 3.34 and a quick ratio of 2.89. The stock has a market cap of $639.13 million, a P/E ratio of 12.25 and a beta of 2.64.
A number of equities research analysts have recently issued reports on ANIP shares. BidaskClub cut shares of ANI Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, September 19th. Cantor Fitzgerald set a $74.00 target price on shares of ANI Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, October 3rd. ValuEngine raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 23rd. Finally, Canaccord Genuity set a $75.00 price objective on shares of ANI Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 16th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $71.00.
ANI Pharmaceuticals Profile
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.
Recommended Story: Preferred Stock
Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals Inc (NASDAQ:ANIP).
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.